Patient management guided by viability imaging  by Beanlands, Rob S et al.
Michael A. Portman, MD, FACC
The Heart Center
Children’s Hospital and Regional Medical Center
4800 Sand Point Way NE
Seattle, Washington 98105
E-mail: mportm@chmc.org
Frank Cecchin, MD, FACC
Thomas K. Jones, MD, FACC
Julie A. Davis, MD
Flavian M. Lupinetti, MD
PII S0735-1097(01)01523-6
REFERENCES
1. Davis JA, Cecchin F, Jones TK, Portman MA. Major coronary
anomalies in a pediatric population: incidence and clinical importance.
J Am Coll Cardiol 2001;37:593–7.
2. Pellicia A. Congenital coronary anomalies in young patients. J Am Coll
Cardiol 2001;37:598–600.
3. Yoshikawa Y, Yagihara T, Kameda Y, et al. Result of surgical treat-
ments in patients with coronary-arterial occlusive disease after Kawasaki
disease. Eur J Cardiothorac Surg 2000;17:515–9.
4. Miura N, Terai M, Meng TG, Sato T, Niimi H. Serum thrombopoi-
etin levels in Kawasaki disease. Br J Haematol 1998;100:387–8.
5. Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Active remodeling of
the coronary arterial lesions in the late phase of Kawasaki disease:
immunohistochemical study. Circulation 2000;101:2935–41.
Acute Ethanol Exposure Fails to Elicit
Preconditioning-Like Protection in
In Situ Rabbit Hearts Because of Its
Continued Presence During Ischemia
We read the findings of Krenz et al. (1) with great interest. Ischemic
preconditioning remains one intriguing explanation for the associa-
tion of moderate alcohol consumption with lower coronary mortality
(2) and lower case-fatality rate of acute myocardial infarction (MI) (3).
Their finding that the continued presence of ethanol during ischemia
eliminates its preconditioning effect may have important clinical
implications. We previously reported that alcohol use less than 6 h
before acute MI was not associated with a change in peak creatine
kinase level or risk of Q-wave infarction among patients enrolled in
the Determinants of Myocardial Infarction Onset Study (4), consis-
tent with their findings. Interestingly, we found 21% lower peak
creatine kinase levels and 23% lower odds of Q-wave infarction
among patients whose last alcohol consumption occurred 6 to 12 h
prior to infarction, although neither finding reached statistical signif-
icance. Thus, our findings in a clinical population lend support to their
hypothesis that ethanol exposure that ends with sufficient time to be
completely metabolized may have a preconditioning effect on infarct
size, whereas ethanol exposure that persists close to the time of
infarction does not.
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Patient Management
Guided by Viability Imaging
We read with interest the study by Siebelink et al. (1) comparing
positron emission tomography (PET) and single-photon emission
computed tomographic imaging (SPECT)-guided patient man-
agement. The investigators are to be commended for undertaking
this difficult study. However, there are important limitations that
may limit the conclusions drawn.
Patient population. The greatest impact of viability imaging is in
patients with severe left ventricular (LV) dysfunction (2,3). Such
patients are at high risk for events but have the most to gain from
revascularization when significant viable myocardium is detected
(2–4). In the Siebelink et al. study (1), the majority of the patients
(65%) had only mild to moderate LV dysfunction. Thus, it is not
surprising that the overall event rate was low. This low event rate
with the small sample size makes it unlikely that any difference
between the two strategies would be identified.
There was no information regarding angina or prior stress
perfusion imaging, both of which could lead to preselection bias
and could influence decisions for revascularization (even after
viability data are available). All of the patients had preceding
angiograms, which likely biases therapy toward revascularization.
The time from randomization to revascularization was lengthy
(estimated at 115 vs. 132 days). Previous studies have shown that
long waits to revascularization can lead to high mortality rates in
patients with severe LV dysfunction (4). In the Siebelink et al. (1)
study, there were two deaths (2%) awaiting revascularization,
further suggesting that the study population represented a rela-
tively lower-risk group of patients. Furthermore, some of the
benefits of revascularization may have been lost because of the
revascularization delay (4).
Viability imaging. Severe 2-methoxy isobutyl isonitrile (MIBI)
perfusion defects can have viable myocardium by fluorodeoxyglu-
cose (FDG) (5–7). The investigators observed 20% nonviable
myocardium by MIBI and 16% by FDG. A focus on more severe
LV dysfunction would have increased the number of severe defects
and the discrepancies with FDG as observed by others (5–7).
Defects with greater than 50% MIBI uptake were called
“jeopardized.” For ammonia/FDG, only mismatch was considered
“jeopardized.” Recent data indicate that the degree of FDG uptake
relates to the degree of recovery of function (8,9). The use of 50%
cutoff for FDG has been beneficial in directing revascularization
(10). In the current study, it would appear that a fixed defect with
65% MIBI uptake would be considered jeopardized, but 65%
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ammonia uptake matched with FDG may have been called “scar.”
In some patients, this approach could underestimate viable myo-
cardium defined by FDG imaging and bias against directing
patients to surgery after FDG PET.
Sample size (n 5 103). A 20% overall event rate was proposed
based on a previous study (11). The selection of 20% difference
(presumably SPECT 30% and PET 10%) appears arbitrary. This
would represent an overly optimistic 66% relative reduction in
event rate for this relatively low-risk patient population. Smaller
differences would still be clinically relevant particularly for patients
with severe LV dysfunction. At least one ongoing randomized
controlled study will recruit 412 patients with severe LV dysfunc-
tion to show a 30% relative reduction in event rate, based on
previous outcome studies in a similar population (2); the impact of
FDG PET-guided therapy (9) on outcomes and costs will be
compared to standard care in this study.
In summary, the interpretation of the results of the study by
Siebelink et al. (1) is hindered by the limitations common to many
clinical trials, namely those of appropriate patient selection and
sample size. Therefore, it is difficult to draw conclusions regarding
the role of either technique in the most appropriate group of
patients for viability testing—those with severe LV dysfunction.
The study, however, does provoke the need for larger randomized
controlled trials evaluating this problem, some of which are under
way. The researchers should be congratulated on being the first to
take this initiative.
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REPLY
Beanlands and colleagues make some interesting remarks on which
we would like to comment.
The purpose of our study was to evaluate in a prospective,
blinded, and randomized clinical setting what effect positron
emission tomography (PET) and single-photon emission com-
puted tomographic (SPECT) imaging had on patient management
(revascularization or drug treatment) and clinical outcome (cardiac
events) in patients in whom jeopardized myocardium was sus-
pected (1). Therefore, the population in our study resembles the
everyday clinical practice of 103 patients who are candidates for
viability testing. In our population the event rate was 23%, and
there was no significant difference in patient management and
clinical outcome between PET and SPECT-based patient man-
agement. As Beanlands and colleagues state, the clinical relevance
of observed differences often remains arbitrary and may vary with
different patient populations (e.g., severe left ventricular [LV]
dysfunction). However, we believe that in our study the observed
differences in cardiac event rate were not clinically meaningful,
because 19,250 patients should have been included to reach a
significant p value.
Concerning the patient population in our study, we are well
aware of the fact that most patients (65%) had mild to moderate
LV dysfunction. Therefore, conclusions on patients with severe
LV dysfunction should be interpreted with caution, although our
prospective, blinded and randomized study indicates that clinical
outcome might not be different between PET and SPECT-based
management in this category.
At the time we designed the study we used the most appropriate
criteria for the detection of jeopardized myocardium (1). Obvi-
ously, during the study we were not able to incorporate new
insights concerning detection of jeopardized myocardium. If more
patients with severe LV dysfunction were included in our study we
can only speculate whether this would have led to increased
discrepancies between PET and SPECT. It also remains specula-
tive whether these discrepancies would have resulted in different
management and different clinical outcome.
Opposite to what Beanlands and colleagues suggest, we believe
that our study contains no selection bias toward revascularization,
but just addresses the practical clinical question: revascularize or
not, depending on the amount of jeopardized myocardium. The
intended revascularization in our study was planned with an
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